コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 support for inclusion of this molecule in a meningococcal vaccine.
2 ingitidis serogroups included in the current meningococcal vaccine.
3 nactivated influenza vaccine or quadrivalent meningococcal vaccine.
4 lopment not only for gonorrhoea but also for meningococcal vaccines.
5 rvations support the incorporation of Opa in meningococcal vaccines.
6 ructure that may affect the effectiveness of meningococcal vaccines.
7 al, Haemophilus influenzae type b (Hib), and meningococcal vaccines.
8 ome outer membrane protein-based serogroup B meningococcal vaccines.
9 -vaccine era, use of a polyvalent conjugated meningococcal vaccine, and influenza vaccination during
10 s to factor H (fH)-binding protein (fHBP), a meningococcal vaccine antigen, activate classical comple
19 Genome-derived neisserial Ag (GNA) 1870 is a meningococcal vaccine candidate that can be subdivided i
20 Factor H-binding protein (fHbp) is a novel meningococcal vaccine candidate that elicits serum antib
26 tetravalent (serogroups A, C, Y, and W-135) meningococcal vaccine conjugated to diphtheria toxoid at
28 ived 3 doses of outer-membrane protein (OMP) meningococcal vaccine developed in either Cuba or Norway
29 creased in recent years, but the efficacy of meningococcal vaccine during mass vaccination campaigns
30 and cerebrospinal fluid (CSF) samples from a meningococcal vaccine field trial performed in Iquique,
32 a demonstrate the feasibility of preparing a meningococcal vaccine from a single recombinant protein
34 eported in 60 (3%) women in the quadrivalent meningococcal vaccine group and 61 (3%) women in the tri
35 ere first episodes (n=77 in the quadrivalent meningococcal vaccine group vs n=52 in the trivalent ina
36 93 (88%) of 2041 infants in the quadrivalent meningococcal vaccine group were followed up until age 6
37 round the world, and a hexavalent PorA-based meningococcal vaccine has recently been developed in The
38 A significant problem in efficacy trials of meningococcal vaccines has been accurate identification
40 e candidates in the search for comprehensive meningococcal vaccines; however, the formulation of OMP
41 p vaccine), meningococcal disease (conjugate meningococcal vaccine), human papillomavirus (for female
42 re potentially preventable with the licensed meningococcal vaccine in 82.8% of 15 through 24 year old
43 llenge will be effective introduction of new meningococcal vaccines into developing countries, especi
47 opose that outer membrane vesicle-containing meningococcal vaccines may be more efficacious if purged
48 -OMVs as adjuvants or as portions of group B meningococcal vaccines may help improve survival and out
52 ve either an influenza vaccine or a control (meningococcal vaccine, pneumococcal vaccine, or placebo)
55 During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010-2011 and its roll
57 hat for serogroups prevented by quadrivalent meningococcal vaccines, public health response to outbre
58 f tetanus/diphtheria/acellular pertussis and meningococcal vaccines, respectively, was delayed by 1 w
60 was more common in women given quadrivalent meningococcal vaccine than in those given trivalent inac
61 ongoing to develop a serogroup B vaccine and meningococcal vaccines that are immunogenic in infants a
64 d diagnostic of disease in future testing of meningococcal vaccines to improve efficacy analyses.
67 vels elicited by two efficacious serogroup B meningococcal vaccines were measured in a controlled tri
68 i-TT), Vi-polysaccharide (Vi-PS), or control meningococcal vaccine with a computer-generated randomis
69 se data suggest that neither serogroup B OMP meningococcal vaccine would confer protection during a h
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。